Federated genomics analysis market seen doubling by 2030

By AI, Created 5:02 PM UTC, May 18, 2026, /AGP/ – The federated genomics analysis market is projected to grow from $1.64 billion in 2025 to $4.27 billion by 2030 as healthcare systems push for secure ways to analyze genetic data across institutions. The market is being shaped by precision medicine, privacy rules, and broader adoption of cloud and AI tools.

Why it matters: - Federated genomics analysis lets researchers and providers study genetic data across multiple sites without moving raw data, which helps protect patient privacy. - The approach supports cross-border collaboration in precision medicine, where large and diverse datasets are needed to improve diagnosis and treatment. - The market’s expected expansion points to rising demand for privacy-preserving tools in healthcare data infrastructure.

What happened: - The Business Research Company projected the federated genomics analysis market will rise from $1.64 billion in 2025 to $1.98 billion in 2026. - The firm forecast the market will reach $4.27 billion by 2030, implying a 21.2% CAGR from 2026 to 2030. - The company said the market is gaining traction as secure, collaborative genetic analysis becomes more important for researchers and healthcare providers. - The report release included free sample and full-report links: Sample report and Full report.

The details: - The market’s earlier growth was tied to rising genomic sequencing volumes, stricter privacy laws, more multi-center clinical trials, higher precision medicine investment, and stronger high-performance computing infrastructure. - Forecast growth is linked to federated learning in healthcare, cross-border genomic research, tighter cybersecurity for health data, wider use of cloud genomics platforms, and AI-powered genomic interpretation tools. - Expected market trends include privacy-preserving genomic analytics, deeper research collaboration, distributed data management systems, secure multi-site studies, and federated models embedded in clinical genomics workflows. - Federated genomics analysis keeps data at the source site and sends models or queries to multiple institutions instead of transferring raw genetic information. - The structure helps organizations meet data governance rules while overcoming legal and technical barriers to sharing sensitive health data. - Precision medicine is a major growth driver because it depends on large, varied genomic datasets that are difficult to centralize. - In February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022.

Between the lines: - The market forecast suggests privacy and collaboration are no longer competing goals in genomics; vendors are building products to do both. - North America led the market in 2025 because of advanced healthcare infrastructure and strong research capacity. - Asia-Pacific is projected to be the fastest-growing region, which points to expanding genomics investment outside the U.S. and Europe. - The regional outlook also spans South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What’s next: - Market growth will likely track adoption of federated learning, cloud-based genomics, and AI tools in clinical and research settings. - More multi-site studies and cross-border collaborations should increase demand for secure distributed analysis platforms. - The Business Research Company positioned the market as part of a broader shift toward privacy-preserving health data infrastructure.

The bottom line: - Federated genomics analysis is moving from a niche privacy workaround to a core enabler of large-scale genomic research.